Evaluation of Different National Comprehensive Cancer Network Clinical Practice Guidelines in Prostate Cancer for Germline Genetic Testing in Localized and Locally Recurrent Prostate Cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
376 patients, testing was performed prior to radical prostatectomy and salvage lymphadenectomy in 346 (92.
I · Intervention 중재 / 시술
GGT for the PCa-associated genes ATM, BRCA1, BRCA2, CHEK2, TP53, PALB2, MLH1, MSH2, MSH6, PMS2, and HOXB13
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS AND CLINICAL IMPLICATIONS] The GGT criteria outlined in the NCCN guidelines version 1.2022 for nonmetastatic high-risk PCa patients provide a robust framework for identifying patients at a high risk of PGVs. Therefore, GGT should be offered to patients with nonmetastatic PCa in accordance with these GGT criteria.
[BACKGROUND AND OBJECTIVE] Germline genetic testing (GGT) is useful for identifying prostate cancer (PCa).
- p-value p = 0.01
APA
Kachanov M, Volk AE, et al. (2025). Evaluation of Different National Comprehensive Cancer Network Clinical Practice Guidelines in Prostate Cancer for Germline Genetic Testing in Localized and Locally Recurrent Prostate Cancer.. European urology focus, 11(6), 848-854. https://doi.org/10.1016/j.euf.2025.05.021
MLA
Kachanov M, et al.. "Evaluation of Different National Comprehensive Cancer Network Clinical Practice Guidelines in Prostate Cancer for Germline Genetic Testing in Localized and Locally Recurrent Prostate Cancer.." European urology focus, vol. 11, no. 6, 2025, pp. 848-854.
PMID
40517093 ↗
Abstract 한글 요약
[BACKGROUND AND OBJECTIVE] Germline genetic testing (GGT) is useful for identifying prostate cancer (PCa). This study aims to evaluate the GGT criteria according to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines on oncology (NCCN guidelines) for PCa, version 1.2022, for identifying PCa patients to whom GGT at a nonmetastatic stage should be offered.
[METHODS] Consecutive patients referred to our center were assessed using the GGT criteria from the NCCN guidelines version 1.2022. All patients received GGT for the PCa-associated genes ATM, BRCA1, BRCA2, CHEK2, TP53, PALB2, MLH1, MSH2, MSH6, PMS2, and HOXB13. Detection rates of pathogenic or likely pathogenic variants (PGVs) were used to assess the criteria. Additionally, the detection rates of PGVs between different versions of the NCCN guidelines recommended GGT criteria were compared.
[KEY FINDINGS AND LIMITATIONS] Of 376 patients, testing was performed prior to radical prostatectomy and salvage lymphadenectomy in 346 (92.0%) and 30 (8.0%) patients, respectively. We detected 47 PGVs in 46 (12.2%) patients. Logistic regression analyses revealed high-risk PCa characteristics as a significant predictor of PGVs (odds ratio 2.19, 95% confidence interval 1.18-4.13, p = 0.01). Applying the GGT criteria outlined in the NCCN guidelines versions 2.2019 and 3.2024, PGVs were detected in 12.5% and 12.6% of the patients, respectively. Compared with the NCCN guideline version 1.2022, both the testing criteria would have missed five patients with PGVs.
[CONCLUSIONS AND CLINICAL IMPLICATIONS] The GGT criteria outlined in the NCCN guidelines version 1.2022 for nonmetastatic high-risk PCa patients provide a robust framework for identifying patients at a high risk of PGVs. Therefore, GGT should be offered to patients with nonmetastatic PCa in accordance with these GGT criteria.
[METHODS] Consecutive patients referred to our center were assessed using the GGT criteria from the NCCN guidelines version 1.2022. All patients received GGT for the PCa-associated genes ATM, BRCA1, BRCA2, CHEK2, TP53, PALB2, MLH1, MSH2, MSH6, PMS2, and HOXB13. Detection rates of pathogenic or likely pathogenic variants (PGVs) were used to assess the criteria. Additionally, the detection rates of PGVs between different versions of the NCCN guidelines recommended GGT criteria were compared.
[KEY FINDINGS AND LIMITATIONS] Of 376 patients, testing was performed prior to radical prostatectomy and salvage lymphadenectomy in 346 (92.0%) and 30 (8.0%) patients, respectively. We detected 47 PGVs in 46 (12.2%) patients. Logistic regression analyses revealed high-risk PCa characteristics as a significant predictor of PGVs (odds ratio 2.19, 95% confidence interval 1.18-4.13, p = 0.01). Applying the GGT criteria outlined in the NCCN guidelines versions 2.2019 and 3.2024, PGVs were detected in 12.5% and 12.6% of the patients, respectively. Compared with the NCCN guideline version 1.2022, both the testing criteria would have missed five patients with PGVs.
[CONCLUSIONS AND CLINICAL IMPLICATIONS] The GGT criteria outlined in the NCCN guidelines version 1.2022 for nonmetastatic high-risk PCa patients provide a robust framework for identifying patients at a high risk of PGVs. Therefore, GGT should be offered to patients with nonmetastatic PCa in accordance with these GGT criteria.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.